| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Andreea Bălan | |
| Marius Alexandru Moga | |||
| Oana Gabriela Dimienescu | |||
| Ioan Scârneciu | |||
| Barna Barabaș | |||
| Liana Pleș | |||
| P2860 | cites work | Gabapentin for chronic neuropathic pain and fibromyalgia in adults | Q24235709 |
| Botulinum toxin | Q24634441 | ||
| Vesicle-associated membrane protein 4 is implicated in trans-Golgi network vesicle trafficking | Q24649038 | ||
| Botulinum toxin A for the Treatment of Overactive Bladder | Q26764765 | ||
| Structure and function of longin SNAREs | Q26777156 | ||
| On botulinum neurotoxin variability | Q27007548 | ||
| Structural basis of cell surface receptor recognition by botulinum neurotoxin B | Q27643302 | ||
| Central sensitization in urogynecological chronic pelvic pain: a systematic literature review | Q27691406 | ||
| Distribution and colocalization of calcitonin gene-related peptide, tachykinins, and vasoactive intestinal peptide in normal and idiopathic unstable human urinary bladder | Q66829337 | ||
| Vulvar vestibulitis syndrome | Q68967000 | ||
| Inhibition of vacuolar adenosine triphosphatase antagonizes the effects of clostridial neurotoxins but not phospholipase A2 neurotoxins | Q72389951 | ||
| A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trøndelag | Q73270831 | ||
| Human response to botulinum toxin injection: type B compared with type A | Q73508514 | ||
| Preliminary results of suburothelial injection of botulinum a toxin in the treatment of chronic interstitial cystitis | Q81119000 | ||
| Consensus guidelines for the management of chronic pelvic pain | Q81478235 | ||
| Botulinum toxin a injection of the obturator internus muscle for chronic perineal pain | Q81742175 | ||
| Botulinum toxin A for the management of vulvodynia | Q83855243 | ||
| Chronic pelvic pain | Q84332850 | ||
| Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity | Q85651745 | ||
| Chronic Pelvic Pain in Women | Q95556300 | ||
| Understanding and treating vaginismus: a multimodal approach. | Q50673992 | ||
| Efficacy of high doses of botulinum toxin A for treating provoked vestibulodynia. | Q51511369 | ||
| Botulinum toxin type A-a novel treatment for provoked vestibulodynia? Results from a randomized, placebo controlled, double blinded study. | Q51625368 | ||
| What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection. | Q51808327 | ||
| Bafilomycin A1 inhibits the action of tetanus toxin in spinal cord neurons in cell culture. | Q52212498 | ||
| The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a. | Q52312776 | ||
| Chronic pelvic pain: prevalence, health-related quality of life, and economic correlates. | Q53627396 | ||
| Genetic Diversity Within Clostridium botulinum Serotypes, Botulinum Neurotoxin Gene Clusters and Toxin Subtypes | Q56070183 | ||
| Vaginismus: results of treatment with botulin toxin | Q56838299 | ||
| Botulinum Toxin in the Treatment of Refractory Vaginismus | Q56882642 | ||
| Visual analogue scales (VAS): Measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care: Position Paper of the German Society of Allergology (AeDA) and the German Society of A | Q56971253 | ||
| Activation of neurokinin 1 receptors on interstitial cells of Cajal of the guinea-pig small intestine by substance P | Q60733567 | ||
| Novel Treatment of Chronic Bladder Pain Syndrome and Other Pelvic Pain Disorders by OnabotulinumtoxinA Injection | Q28087509 | ||
| Thioredoxins, glutaredoxins, and peroxiredoxins--molecular mechanisms and health significance: from cofactors to antioxidants to redox signaling | Q28389739 | ||
| The use of medicinal herbs in gynecological and pregnancy-related disorders by Jordanian women: a review of folkloric practice vs. evidence-based pharmacology. | Q30251872 | ||
| A review of the available clinical therapies for vulvodynia management and new data implicating proinflammatory mediators in pain elicitation | Q31108618 | ||
| Vaginismus Treatment: Clinical Trials Follow Up 241 Patients | Q33715869 | ||
| Biofeedback is superior to electrogalvanic stimulation and massage for treatment of levator ani syndrome. | Q33759290 | ||
| Draft Genome Sequence of Weissella oryzae SG25T, Isolated from Fermented Rice Grains | Q33949089 | ||
| ATP as a peripheral mediator of pain | Q33951892 | ||
| Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons | Q34154552 | ||
| Vaginismus | Q34272013 | ||
| Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence | Q34376940 | ||
| Homotypic fusion of early endosomes: SNAREs do not determine fusion specificity | Q34479771 | ||
| Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial | Q34571431 | ||
| Botulinum neurotoxin type A is internalized and translocated from small synaptic vesicles at the neuromuscular junction. | Q34614163 | ||
| Thioredoxins and glutaredoxins: unifying elements in redox biology | Q34998212 | ||
| Botox treatment for vaginismus | Q35015518 | ||
| Possible mechanisms for the effects of botulinum toxin on pain | Q35060554 | ||
| Evidence for antinociceptive activity of botulinum toxin type A in pain management | Q35187501 | ||
| Botulinum toxin A: its expanding role in dermatology and esthetics | Q35202772 | ||
| Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept. | Q35250681 | ||
| Towards new uses of botulinum toxin as a novel therapeutic tool | Q35534477 | ||
| Receptor binding enables botulinum neurotoxin B to sense low pH for translocation channel assembly. | Q35626467 | ||
| Adverse Effects of Plant Food Supplements Self-Reported by Consumers in the PlantLIBRA Survey Involving Six European Countries. | Q35940136 | ||
| Botulinum toxin: mechanisms of action | Q36009295 | ||
| Vulvodynia: strategies for treatment | Q36312590 | ||
| Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. | Q36373708 | ||
| A conceptual model for the pathophysiology of vulvar vestibulitis syndrome | Q36486381 | ||
| A retrospective study of the management of vulvodynia | Q36566509 | ||
| Safety and efficacy of botulinum toxin type A following long-term use. | Q36656478 | ||
| Myofascial dysfunction associated with chronic pelvic floor pain: management strategies | Q36951353 | ||
| Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. | Q36995681 | ||
| Refractory idiopathic urge urinary incontinence and botulinum A injection. | Q37004158 | ||
| Thioredoxins and glutaredoxins as facilitators of protein folding. | Q37106759 | ||
| Botulinum toxin type A (BOTOX) for refractory myofascial pelvic pain | Q37133057 | ||
| Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. | Q37281713 | ||
| Clinical trial: effects of botulinum toxin on Levator ani syndrome--a double-blind, placebo-controlled study | Q37315102 | ||
| Botulinum neurotoxin: a marvel of protein design | Q37710092 | ||
| The role of botulinum toxin in management of pain: an evidence-based review | Q37768320 | ||
| The life history of a botulinum toxin molecule | Q38091815 | ||
| Prevalence of chronic pelvic pain among women: an updated review | Q38198505 | ||
| Botulinum toxin A, brain and pain | Q38219087 | ||
| Botulinum neurotoxins: genetic, structural and mechanistic insights. | Q38224215 | ||
| Botulinum-A Toxin's efficacy in the treatment of idiopathic overactive bladder | Q38399972 | ||
| On the translocation of botulinum and tetanus neurotoxins across the membrane of acidic intracellular compartments. | Q38573906 | ||
| Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology | Q39207459 | ||
| Persistent therapeutic effect of repeated injections of onabotulinum toxin a in refractory bladder pain syndrome/interstitial cystitis. | Q39235896 | ||
| Double anchorage to the membrane and intact inter-chain disulfide bond are required for the low pH induced entry of tetanus and botulinum neurotoxins into neurons. | Q39500669 | ||
| Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes | Q40100085 | ||
| Botulinum Toxin A Injections Into Pelvic Floor Muscles Under Electromyographic Guidance for Women With Refractory High-Tone Pelvic Floor Dysfunction: A 6-Month Prospective Pilot Study | Q40274549 | ||
| Inhibition of botulinum neurotoxins interchain disulfide bond reduction prevents the peripheral neuroparalysis of botulism. | Q40451664 | ||
| Notes on Bacillus botulinus | Q40723522 | ||
| Identification and characterization of a novel botulinum neurotoxin. | Q41245604 | ||
| Application of botulinum toxin in pain management | Q41849757 | ||
| The first non Clostridial botulinum-like toxin cleaves VAMP within the juxtamembrane domain | Q42408273 | ||
| A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. | Q42664757 | ||
| Prevalence of pelvic musculoskeletal disorders in a female chronic pelvic pain clinic. | Q43853266 | ||
| Botulinum toxin decreases hyperalgesia and inhibits P2X3 receptor over-expression in sensory neurons induced by ventral root transection in rats | Q43901776 | ||
| Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment | Q44818674 | ||
| P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin. | Q44971837 | ||
| Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats | Q45062115 | ||
| Effect of botulinum toxin on detrusor overactivity induced by intravesical adenosine triphosphate and capsaicin in a rat model | Q46393825 | ||
| Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. | Q46644837 | ||
| Importance of pelvic muscle tenderness evaluation in women with chronic pelvic pain | Q46925303 | ||
| Pilot study of botulinum toxin type A in the treatment of chronic pelvic pain associated with spasm of the levator ani muscles | Q47751142 | ||
| Another type of Clostridium botulinum | Q47763568 | ||
| Hsp90 is involved in the entry of clostridial neurotoxins into the cytosol of nerve terminals. | Q48163816 | ||
| Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. | Q48510314 | ||
| Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup | Q48525644 | ||
| Thioredoxin and its reductase are present on synaptic vesicles, and their inhibition prevents the paralysis induced by botulinum neurotoxins. | Q48543733 | ||
| Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study | Q48558961 | ||
| Botulinum toxin a has antinociceptive effects in treating interstitial cystitis | Q48827566 | ||
| Botulinum neurotoxin type A injections for vaginismus secondary to vulvar vestibulitis syndrome | Q48881645 | ||
| Identification of a Botulinum Neurotoxin-like Toxin in a Commensal Strain of Enterococcus faecium. | Q50207264 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P921 | main subject | enzyme | Q8047 |
| female reproductive system disease | Q5442760 | ||
| bacterial protein | Q64923821 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P577 | publication date | 2018-04-21 | |
| P1433 | published in | Toxins | Q15724569 |
| P1476 | title | Therapeutic Approaches of Botulinum Toxin in Gynecology. | |
| P478 | volume | 10 |
| Q92527863 | Botulinum Toxin a Valuable Prophylactic Agent for Migraines and a Possible Future Option for the Prevention of Hormonal Variations-Triggered Migraines |
| Q89683175 | Can Botulinum Toxin A Play A Role In Treatment Of Chronic Pelvic Pain Syndrome In Female Patients?-Clinical and Animal Evidence |
| Q92689841 | Evaluating the safety and potential activity of URO-902 (hMaxi-K) gene transfer by intravesical instillation or direct injection into the bladder wall in female participants with idiopathic (non-neurogenic) overactive bladder syndrome and detrusor o |
Search more.